home
about
platform
science
news
Investor Relations
contact
中
/
EN
news
2026-07-13
APPLICATION FOR CLINICAL TRIAL ON LP-003 FOR THE INDICATION OF PEANUT ALLERGY APPROVED BY THE FDA, MARKING A KEY MILESTONE IN GLOBAL CLINICAL LAYOUT
more
2026-07-03
[Join Us!] Director of Manufacturing & Process Technology
more
2026-07-03
[Join Us!] VP of CMC
more
2026-03-25
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Omalizumab
more
2025-03-03
Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025
more
1
2
